Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 275.03 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 ... 9 10 11 12 13 14 15 16 Next > What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals January 03, 2022 Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: Via Benzinga Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference January 03, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates December 31, 2021 Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session December 27, 2021 Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%... Via Benzinga 51 Biggest Movers From Yesterday December 28, 2021 Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... Via Benzinga 34 Stocks Moving In Monday's Mid-Day Session December 27, 2021 Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY... Via Benzinga BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops December 27, 2021 Patients who received the drug didn't improve in the six-minute walking test. Via Investor's Business Daily FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol December 23, 2021 The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is... Via Benzinga The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review December 23, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... Via Benzinga Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C December 22, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy December 22, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies December 21, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail December 21, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... Via Benzinga Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease December 20, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout December 20, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire 2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022 December 14, 2021 Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ... Via Benzinga Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1 December 14, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More December 06, 2021 The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... Via Benzinga Exposures Product Safety Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021 December 02, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentations at Upcoming Investor Conferences November 23, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock November 22, 2021 RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M... Via Benzinga How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 November 22, 2021 Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. Via Investor's Business Daily Expert Ratings For Alnylam Pharmaceuticals November 22, 2021 Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 November 22, 2021 Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: Via Benzinga 10 Biggest Price Target Changes For Monday November 22, 2021 MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... Via Benzinga Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day November 19, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? November 18, 2021 Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... Via Benzinga Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan November 18, 2021 Novo Nordisk is buying an RNA interference company. Via Investor's Business Daily Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021 November 13, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Virtual R&D Day November 12, 2021 From Alnylam Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 ... 9 10 11 12 13 14 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.